Onesource Specialty Pharma Limited
ACTIVE
ISIN: INE013P08018
Issuer Details
Issuer Name
ONESOURCE SPECIALTY PHARMA L...
Type of Issuer
Non PSU
Sector
Healthcare
Coupon Rate
2.5%
Industry
Pharmaceuticals & Biotechnol...
Issuer nature
-
Corporate Identity Number (CIN)
U74140KA2007PLC043095
Name of the Lead Manager
-
Registrar
Integrated Enterprises (Indi...
Name of Debenture Trustee
Vistra ITCL (India) Limited
Instrument Details
Instrument name as on NSDL
2.50% UNSECURED UNRATED UNLI...
Face Value (in ₹)
10000
Total Issue size( in ₹ Cr.)
80
Category of Instrument
OTHERS
Allotment Date
14-02-2023
Redemption Date
14-06-2026
Whether Secured or Unsecured
Unsecured
Put Option Date
-
Call Option Date
-
Seniority in Repayment
-
Cash Flow Schedule
Cash Flow Event
Record Date
Interest
09-02-2024
Interest
09-02-2024
Interest
09-02-2025
Interest
09-02-2025
Interest
09-02-2026
Interest
09-02-2026
Redemption
09-03-2026
Redemption
09-03-2026
Redemption
09-04-2026
Redemption
09-04-2026
Redemption
09-05-2026
Redemption
09-05-2026
Redemption
09-06-2026
Redemption
09-06-2026
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
Similar Bonds
About Onesource Specialty Pharma Limited bond with ISIN: INE013P08018
In the competitive landscape of fixed income securities, detailed and comprehensive information is vital for both investors and market analysts. This bond, identified by the unique ISIN INE013P08018, represents a significant financial instrument. Issued by ONESOURCE SPECIALTY PHARMA LIMITED, it comes with the following description: "2.50% UNSECURED UNRATED UNLISTED REDEEMABLE NON CONVERTIBLE DEBENTURE. LETTER OF ALLOTMENT DATE OF MATURITY 14/06/2026.". Although the bond is currently marked as active, its structure and historical context provide valuable insights into the world of debentures and non-convertible securities. The issuer, ONESOURCE SPECIALTY PHARMA LIMITED, classified as N/A, plays an essential role in the market despite some details such as sector, industry, and issuer nature not being explicitly provided. Key identifiers like the Corporate Identification Number (CIN) U74140KA2007PLC043095 further bolster its credibility. With a coupon rate of 2.5, this instrument has been meticulously managed with the assistance of Integrated Enterprises (India) Ltd., Chennai and under the oversight of Vistra ITCL (India) Limited, ensuring a strong operational framework. Examining the technical specifications, the bond’s face value is 10000 with an issue size of 80. It was allotted on 2/14/2023 and is scheduled for redemption on 6/14/2026. Categorized under "OTHERS" and defined as Unsecured, the instrument is structured to meet specific investment objectives. Although options such as call or put are not applicable in this instance, the core attributes remain detailed and robust. A critical element in evaluating any fixed income instrument is its credit rating. No credit rating information is available for this bond. This insight helps potential investors understand that while the ratings spectrum is broad, a lower rating can indicate higher risk, prompting careful consideration before investing. The security measures add another layer of assurance. The asset cover is described as follows: No specific asset cover description available. – a feature that, while requiring further inquiry for complete details, underscores the issuer’s commitment to providing some level of investor protection. Furthermore, the bond is supported by several documents. There are no additional documents available for this bond. These documents serve as a reference for additional details and provide transparency to interested parties. Additionally, there are similar bonds in the market such as the bond with ISIN INE013P07010 having a coupon rate of 12.5% and the bond with ISIN INE013P07028 having a coupon rate of 12.5% and the bond with ISIN INE013P08117 having a coupon rate of 4%. Such comparable instruments offer a broader perspective on market positioning and allow investors to perform benchmark analysis. This detailed description is crafted to meet rigorous content standards and to offer exhaustive insights into every facet of the bond’s structure. Investors, analysts, and researchers alike can derive substantial value from this narrative, which underscores both the instrument’s inherent characteristics and its broader market positioning. Such elaborate coverage enhances investor confidence by providing a rich, comprehensive content base. Every element from issuance details to security measures and comparative insights is meticulously presented to facilitate an informed and robust market understanding.